Pine Pharmaceuticals, Tonawanda, NY
Is Pine Pharmaceuticals registered with the FDA as a 503B outsourcing facility?
No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels its entry 503B. The list does name Pine Pharmaceuticals, LLC in Tonawanda, NY, a close but not exact match shown below.
Does Pine Pharmaceuticals hold a New York pharmacy license?
State pharmacy license records for New York are not checked: the Office of the Professions’ online verification search requires an access key and a check that the user is a person, and its bulk verification files are released only on request. This index reads only that state’s board actions. The California State Board of Pharmacy also lists nonresident license NSF 122 for Pine Pharmaceuticals Llc, Tonawanda, NY, status Active, as of Nov 6, 2026. The Delaware Division of Professional Regulation also lists nonresident license AD-0010096 for Pine Pharmaceuticals, TONAWANDA, NY, status Active, license A9-0001540 for Pine Pharmaceuticals, TONAWANDA, NY, status Expired, license AA-0000002 for Pine Pharmaceuticals, TONAWANDA, NY, status Expired and license AA-X0000002 for Pine Pharmaceuticals, TONAWANDA, NY, status Closed, as of Nov 10, 2026. The Michigan Department of Licensing and Regulatory Affairs also lists nonresident license 5301011319 for Pine Pharmaceuticals LLC, Tonawanda, NY, status Active, as of Nov 10, 2026.
Has Pine Pharmaceuticals had a state board action or FDA letter?
FDA letters: no matching record found on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026; the page lists 4 Form 483s (latest Nov 14, 2025) for Pine Pharmaceuticals. State board actions: no New York State Education Department action under this exact name and city was found in the New York State Education Department’s list of Board of Regents disciplinary actions against pharmacy establishments (actions dated Jan 14, 1994 to May 19, 2026) on Nov 8, 2026.
FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.
- Names in FDA records
- Pine Pharmaceuticals
- Location
- Tonawanda, NY
- Type as FDA labels it
- 503B
- FDA 503B list
- No matching record found
- Form 483s on FDA’s actions page
- 4
- Warning letters on FDA’s actions page
- 0
- Latest action on that page
- Nov 14, 2025
- FDA Data Dashboard inspections
- 7 inspections: 5 OAI, 1 VAI, 1 NAI; 6 published Form 483s
- Form 483 text on this page
- 5 Form 483s, 29 observations
- State board records
- Not checked (license records); board actions matched: 0
FDA inspections and letters
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Pine Pharmaceuticals, a 503B facility, with 5 dated actions.
| Document | |||
|---|---|---|---|
| Nov 14, 2025 | Form 483 | 483 Issued 11/14/2025 | fda.gov |
| Sep 30, 2024 | Form 483 | 483 Issued 09/30/2024 | fda.gov |
| Mar 14, 2024 | Regulatory meeting | Regulatory Meeting Held 03/14/2024 | Not linked by FDA |
| Sep 19, 2023 | Form 483 | 483 Issued 9/19/2023 | FDA copy (archived) |
| May 14, 2021 | Form 483 | 483 Issued 05/14/2021 | fda.gov |
A Form 483 lists investigator observations, not a final FDA determination.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists Pine Pharmaceuticals, LLC, Tonawanda, NY (FEI number 3010943533), matched to this page by exact name, city and state. It lists 7 inspections: 5 OAI, 1 VAI, 1 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Nov 14, 2025 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3010943533 | 1282102 |
| Sep 30, 2024 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3010943533 | 1246936 |
| Sep 19, 2023 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3010943533 | 1218206 |
| May 14, 2021 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3010943533 | 1141929 |
| Apr 26, 2018 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3010943533 | 1049641 |
| Oct 9, 2015 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3010943533 | 945292 |
| Oct 17, 2014 | No Action Indicated (NAI) | Drug Quality Assurance (Drugs) | 3010943533 | 900138 |
Form 483s FDA has published for this site
- Nov 14, 2025: Form 483 to Pine Pharmaceuticals, LLC, published Jan 22, 2026. fda.gov
- Sep 30, 2024: Form 483 to Pine Pharmaceuticals, LLC, published Feb 12, 2025. fda.gov
- Sep 19, 2023: Form 483 to Pine Pharmaceuticals, LLC, published Nov 1, 2023. fda.gov
- May 14, 2021: Form 483 to Pine Pharmaceuticals, LLC, published Sep 24, 2021. fda.gov
- Oct 24, 2018: Form 483 to Pine Pharmaceuticals, LLC, published Jan 17, 2024. fda.gov
- Oct 23, 2015: Form 483 to Pine Pharmaceuticals, LLC, published Jan 17, 2024. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 29 numbered observations in all, across 5 inspections ending Oct 23, 2015 to Sep 30, 2024. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Aug 5, 2024 to Sep 30, 2024: 9 observations
- Firm on the cover
- Pine Pharmaceuticals, LLC, 355 Riverwalk Pkwy, Tonawanda, NY 141 50-5837
- FEI number
- 3010943533
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 158-15 Liberty Avenue Jamaica, NY 11433
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.
Specifically,
l . On 9/10/24 during the production of Lidocaine HCL 4% Ophthalmic Solution, 3mL bottle, Lot# <Redacted B4> Exp: March 5, 2025, on the <Redacted B4> filling machine, it was observed that open bottles containing sterile product being placed in a non-HEPA filtered <Redacted B4> from the <Redacted B4> lLFH( <Redacted B4> filing area) to <Redacted B4> LFH <Redacted B4> (capping area). In addition, no environmental monitoring is being conducted on the <Redacted B4>. Lastly, your firm's smoke study entitled <Redacted B4> (2/27/24) demonstrates that the air is flowing from the <Redacted B4> (capping area) to the <Redacted B4> (filling area) creating turbulent airflow which can increase the level of particulates during the filling operations.
2. Your firm failed to provide justification to support that air velocity and airflow patterns determined in the <Redacted B4> Recertification (February 2024) in your <Redacted B4> flow hoods are adequate to ensure the protection of drug products from turbulent airflow. ...
Observation 2
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
I. Your firm's environmental monitoring specifications were inadequate (alert <Redacted B4> and action 1 <Redacted B4> until December 21, 2023. During that time your firm had one ISO 5 EM failure on 12/5/23, 2 cfu for personnel identified as Micrococcus luteus (operators' right glove) during the production of Bevacizumab 2.5 mg/0 .1 mL, lot <Redacted B4> EXP: 04/03/2024 within hood <Redacted B4> located in Suit~wi Buffer Roomlblfl as documented in NONC-2023-1393. Your firm released the batch based solely on fmished product testing and deemed the impact of this event as minor. In addition, from 12/5/2023 through 08/23/2024 your firm had a total of approximately 16 environmental monitoring failures for personnel, surface and non-viable particulate monitoring within the ISO 5 environment and all <Redacted B4> batches were released solely based on finished product testing.
production ofBevacizumab 2.5 mg/0 .1 mL, lot il(b)(4) EXP: 04/03/2024 within hood (b)(4) located in Suit~wi Buffer Roomlblfl as documented in NONC-2023-1393. ...
Observation 3
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.
Specifically, on 9/10- 9/11/2024 improper aseptic technique was observed during the production of the following Lidocaine HCL 4% Opthalmic Solution, Batch <Redacted B4> EXP: March 5, 2025 in Suite and batches produced in Suit <Redacted B4> Room <Redacted B4> Tropicamide Phenylephrine lnj . 15mL, Lot <Redacted B4> EXP: March 5, 2025 in <Redacted B4> Avastin Pooling IV bag, Lot <Redacted B4> Exp: January 16, 2025 in <Redacted B4> Povidone-Iodine Opthalmic lmL, Lot <Redacted B4> Exp: February 8, 2025 in <Redacted B4> and Bevacizumab Inj. 1.25MG/0.05 ML, Batch <Redacted B4> EXP; January 9, 2025 in <Redacted B4>
1. The operators utilize goggles that have holes across the top allowing for egress of potential particulates from the operators' exposed skin. The goggles are part of the sterile gowning used for operators in Suites <Redacted B4>
2. The operator wiped down the tip/cap, <Redacted B4> tray bags, syringes, and IV bags with a sterile wipe and placed them in the ISO 7 area instead of wiping and immediately placing in the ISO 5 hood. ...
Observation 4
Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.
Specifically,
1. Your firm's SOP, SOP-OO7 titled "Facility Cleaning/Disinfecting", revision 35 dated 10 April 2024, had instructions fo«6)(4} Jcontact time when using[(ol(4) Jand ~5)(4) Jin the disinfection ofyour classified areas including the ISO 50C b)(4) Your firm failed to document contact times in your Room and 6 -i cleaning logbooks to ensure your
procedure was followed.
For example, during the inspection, I reviewed the following cleaning logbooks and observed there was no documentation and evidence of the [(b}(4} I contact time in your: a. (6)(4 Cleaning[t>J(4) ] logbook; LOG-329; dated 12/30/2023 covering cleaning for all cleaned between 01/04/2024 to 08/08/2024.
b. Cleaning Log of Aseptic Compounding Clean Room Suite l<4) LOG-385; dated 03/14/2024 covering cleaning of the ISO 7 clean room from 03/14/2024 to 08/08/2024.
2. Your firm failed to adequately clean and sanitize your capper which is utilized in your <Redacted B4> aseptic filling process inside your ISO 5 1aminar flow hood. Your firm. ...
Observation 5
Separate or defmed areas to prevent contamination or mix-ups are deficient regarding the manufacturing and processing operations.
Specifically,
Your firm failed to have separate dedicated facilities to prevent cross contamination of non-penicillin beta-lactam drug products that are repackaged in the same facility as non-beta-lactam drug products. For example.
a. The entry and exit for the non-penicillin beta-lactam suites (#148) share the same corridor <Redacted B4> with the entries (#156) and exit (#1 <Redacted B4> to the other non-beta-lactam drug products manufacturing suite. You produce the following but not limited to non-beta-lactam products; Bevacizumab 2.5 mg/0. lmL, Vancomycin lmg/0.lMl, LIDO-PHEN 1%-1.5%(l mL) in Suite(bl{,I (Buffo <Redacted B4> with entry through door #156 and exit through door #161.
b. The airflow flows from your non-penicillin beta-lactam suites #148 and 149 into corridor (C05) which is shared with the non-beta-lactarn manufacturing suites. ...
Observation 6
There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Specifically,
1. Your firm conducted inadequate investigations as root causes were not supported through scientific rationale when the following <Redacted B4> flow hoods failed their performance tests due to media or gasket leaks for the following: Buffer Room <Redacted B4> , Model # <Redacted B4> and Buffer Room -Mode <Redacted B4> Buffer Room <Redacted B4> Model <Redacted B4> , Buffer Room <Redacted B4> Model <Redacted B4> Buffer Room <Redacted B4> Model <Redacted B4> . Approximately , <Redacted B4> batches, dating back to the previously passed certification, August 2023 were released based on environmental monitoring results which is determined to be inadequate as critical product contact surfaces are not being assessed, non-viable -particulate monitoring is only being conducted at the <Redacted B4> of the production run and finished product testing. The following batches that have not been adequately evaluated and are on the market within expiration include the following: ...
Observation 7
Your firm failed to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.
Specifically,
1. Your firm's Procedure titled, SOP 061,"Visual Inspection Finished Products", vs. 18 dated 27 May 2024 is deficient as you failed to implement adequate specifications to prevent significant product quality issues from occurring. You have been producing and releasing several lots of Bevacizumab drug products with extremely high levels ofvisible particulates.
2. You failed to adequately investigate and determine the root cause of too many inherent/intrinsic visible particulates defects contamination in multiple batches ofBevacizumab l .25mg/0.05mL found out of limit or above alert limits after your first 100% visual inspections. ...
Observation 8
Written procedures are not established that describe the in-process controls, tests and examinations to be conducted on appropriate samples of in-process materials of each batch.
Specifically,
1. Your firm failed to adequately demonstrate that your process is reproducible and can produce products that consistently meets predetermined specifications for Bevacizumab 1.25mg/0.5ml Injection. For example, your firm lacks in-process weight or volume verification utilizing a calibrated instrument. Since September 2023, you have received approximately 260 complaints for either: empty syringe/air pocket (air bubble), depressed syringe/underfilled and insufficient fill volume. Furthermore, your Quality Unit has not initiated a corrective and/or preventative action to address these complaints and a possible plan to mitigate complaints such as these in the future.
2. Your firm 's Defect limit working document titled, MW A-048,"Percentage Defect Alert and Action Limit", rev.3 dated August 27, 2024 governing the conduct of 100% <Redacted B4> Ivisual inspection of your finished sterile drug products lack action levels for significant individual defects which will require investigations. ...
Observation 9
Actual yield and percentages of theoretical yield are not detennined at the conclusion of each appropriate phase of manufacturing processing, packaging and holding of the drug product.
Specifically, your firm failed to adequately calculate the actual and theoretical yields at each phase of production. For example, your firm is inappropriately calculating batch yields by leaving out all Visual Inspection defects which potentially account for up to <Redacted B4> C4 % loss of the batch. There is no scientifically sound justification for the failure of reporting Inherent/Intrinsic visible particulate defects and there is no scientific justification for the <Redacted B4> inherent particulate rejects for Bevacizumab l.25mg/0.05mL Inj., Lot <Redacted B4> EXP:8/17/24; as they were not considered in neither the percent defect calculations nor the yield calculations (actual versus theoretical yield).
Inspection Sep 6, 2023 to Sep 19, 2023: 7 observations
- Firm on the cover
- Pine Pharmaceuticals, LLC, 355 Riverwalk Pkwy, Tonawanda, NY 14150-5837
- FEI number
- 3010943533
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 158-15 Liberty Avenue Jamaica, NY 11433
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
The quality control unit lacks the responsibility and authority to approve and reject all in process materials and drug products.
Specifically,
A. Your firm did not provide scientific justification as to why your drug product "EPI-CAINE 0.025%-0.75% INJ llML)~ SDV", lot# <Redacted B4>, which is documented to have "all other defects" (specification <Redacted B4> result 3 %), did not necessitate investigation to identify root cause. "All other defects" is identified in the batch record to include critical product quality defects such as visible particulate (5 units), and seal defect (11 units). Lot# <Redacted B4> was released on 11/22/2022.
B. On 6/15/2023, your firm released blended drug product "TROPI-PHEN(@ <Redacted B4> OPHTH SOL (15 mL) Lot# <Redacted B4> Exp. 10/25/2023 that failed 200% VI, 1st and 2na AQL inspections after updating procedure "MWA-030, Rejection and Acceptance <Redacted B4> to change the defect category of particulate matter from critical to major without providing scientific justification.
C Your firm lacks adequate acceptance criteria for critical rejects found during visual inspection processes. ...
Observation 2
There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Specifically,
A. Your firm failed to conduct a thorough investigation into the possible root cause(s) of defective units uncovered during visual inspection. Your firm released your blended product "LIDOPHEN 1%-1.5% (lML) SDV" Lot# <Redacted B4> which failed two 100% visual and AQL instructions after a third 100% and AQL inspection was conducted with a passing result. Lot <Redacted B4> exp. 12/12/2023, was deemed free from defective units and suitable for release. Lot# <Redacted B4> was released on 8/1712023.
B. Your firm failed to conduct adequate investigations relating to complaints COMP-2022-3212, COMP-2022-3290, COMP-2022-3313, and COMP-2022-3314 received for released product Epi-Caine 0.025%-0.75% INJ (l ML) SDV. Your firm confirmed particulate matter in 1 unit of your retains; however did not further identify identify the particulate.
C. During the February 2023 recertification your firm had a HEPA filter leak test failure in one of the LAFHs <Redacted B4> Serial# <Redacted B4>. ...
Observation 3
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.
Specifically, on September 7, 2023, during the production of"BEVACIZUMAB 1.25MG/0.05ML INJ 11-SCLS :MN" lot # <Redacted B4> your production technician <Redacted B4> was observed touching (where their sterile sleeve was resting on) the ISO-5 classified area work surface LAFH <Redacted B4> Serial# <Redacted B4>. According to your procedure SOP-134 Aseptic Environmental Monitoring Plan, no PM sampling is obtained from operator sleeves during production.
Observation 4
Personnel were observed conducting aseptic manipulations where the movement of "first air" in the ISO 5 area is blocked or disrupted.
On September 14, 2023, during production of "BEVACIZUMAB 1.25 mg/0.05 ML INJ-NJ TB" in the ISO 5 classified <Redacted B4> air flow hood <Redacted B4>, Serial #: <Redacted B4>, the setup or placement of <Redacted B4> Syringe Filler <Redacted B4> and the sterile syringe allowed technician <Redacted B4> to block first pass air when making sterile connections.
Observation 5
Production areas have difficult to clean or contain porous, particle generating, or visibly dirty equipment or surfaces.
Specifically, the ISO-5 LAFHs, have difficult to clean electrical and gas outlets located within the inner side of the ISO-5 hood, adjacent to the critical compounding surface.
Observation 6
Smoke studies were inadequately performed under dynamic conditions.
Specifically, air visualization studies ("smoke studies") performed in your ISO 5 classified <Redacted B4> airflow hood <Redacted B4> Serial#: <Redacted B4> demonstrates that smoke is flowing upward and in a back current above the ISO-5 hood, forming eddies where the air seemed to recirculate above the operators head.
Observation 7
Your outsourcing facility did not submit a report to FDA identifying the drugs compounded during the previous six month period.
Specifically, the following products were compounded and not identified on your report submitted on June 2023:
• Epinephrine 4 mg/250mL
• Epinephrine 5 mg/250mL
• Epinephrine 8 mg/250mL
• Norepinephrine 4 mg/250mL
• Norepinephrine 8 mg/250mL
• Norepinephrine 16 mg/250mL
• Phenylephrine HCl 20 mg/250mL
• Phenylephrine HCl 25 mg/250mL
• Phenylephrine HCl 40 mg/250mL
• Phenylephrine HCl 50 mg/250mL
• Vasopressin 0.2U/mL in NS l00mL
• Vasopressin 0.4U/mL in NS l00mL
Inspection May 3, 2021 to May 14, 2021: 5 observations
- Firm on the cover
- Pine Pharmaceuticals, LLC, 355 Riverwalk Pkwy, Tonawanda, NY 14150-5837
- FEI number
- 3010943533
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 158-15 Liberty Avenue Jamaica, NY 11433
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Specifically,
(A) During finished product release testing of <Redacted B4> (Lot <Redacted B4>), your contract lab obtained an OOS potency result of 105.2% (spec. <Redacted B4>) on 3/24/ 2021. Re-analysis of the sample (104.0%, 104.6%, and 105.4%) confirmed the initial OOS result. Your investigation concluded, without adequate supporting evidence, that the most probable root cause was "a lack of reliability in the method used to weigh the isotope during production" and the lot was approved for release on 4/5/ 2021 <Redacted B4> vials of <Redacted B4> (Lot # <Redacted B4> Exp. 09/05/ 2021) were distributed on 4/5/2021.
(B) During finished product release testing of <Redacted B4> Lot # <Redacted B4>, your contract lab obtained an OOS potency result of 81.9% (specification <Redacted B4> on 9/4/2020. The Phase 1 investigation of OOS # 87 by the contract lab did not identify any lab error. ...
Observation 2
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.
Specifically,
(A)
<Redacted B4> are filled into <Redacted B4> empty vials. Prior to filling, the <Redacted B4> glass vials which were <Redacted B4> in the ISO 7 Buffer Room. The aseptic filling process performed inside the ISO 5 LAFW requires <Redacted B4> . After filling, the vials are transferred to ISO 7 Buffer Room for <Redacted B4> Environmental monitoring is not performed during the <Redacted B4> process. There is no assurance that such practice does not expose the interior of the sterile vials to less than ISO 5 quality air.
(B) During aseptic processing of <Redacted B4> (Lot# <Redacted B4>) on 5/4/2021, we observed that the operators did not sanitize all materials prior to introducing into the ISO 5 hood except for the large bulk compounded IV bags. The Director of QA stated their procedure does not require operators to sanitize or wipe down the materials immediately before placing the materials into the ISO 5 hood since it was previously wiped down in the ISO 7 Anteroom. ...
Observation 3
The quality control unit lacks responsibility to approve and reject all procedures or specifications impacting on the identity, strength, quality and purity of drug products.
Specifically, the following lots of products were released and distributed based on the result obtained using potency test method which has not been validated:
This observation is a repeated objectionable condition reported during the previous inspection of 2015 and 2016 Warning Letter.
Observation 4
Laboratory controls do not include the establishment of scientifically sound and appropriate specifications, standards, sampling plans and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling and drug products conform to appropriate standards of identity, strength, quality and purity.
Specifically, Growth promotion testing is not performed for the in-house prepared growth media <Redacted B4> <Redacted B4> used for media fills, such as the simulation of aseptic filling of eye drop product and large volume parenteral drug products. Bulk <Redacted B4> was used in the growth media preparation for the aseptic process qualification of operator <Redacted B6> on 9/16/20201 <Redacted B6>, operator <Redacted B4> on 9/29/20201 <Redacted B4> and operators <Redacted B6> on 4/22/2021 <Redacted B4>. Growth promotion testing were not performed for the prepared media used in these aseptic process simulations to assure media viability to allow growth of microorganisms.
Observation 5
Records of the calibration checks and inspections of automatic, mechanical or electronic equipment, including computers or related systems are not maintained.
Specifically, the temperature sensors and the pressure sensor of the <Redacted B4> have not been calibrated since its installation in February 2018. This <Redacted B4> is used in sterilizing non-product materials which are used in the ISO 5 LAFW. The bottle trays, cap trays, and vial trays which were <Redacted B4> around 4/19/2021-4/28/2021 were used for the production of <Redacted B4> (Lot # <Redacted B4>) on 4/22/2021 and for the production of <Redacted B4>, <Redacted B4> (Lot # <Redacted B4>) on 5/3/2021.
Inspection Apr 26, 2018: 3 observations
- Firm on the cover
- Pine Pharma ce ut ica ls, LLC, DDRESS 355 Riv e r walk Pkwy
- FEI number
- 3010943533
- Establishment type on the cover
- Outsourcing Facility CI TY, S TATE. ZIP CODE, COUNTRY Tonawanda , NY 14150 - 583 7
- FDA district office on the cover
- 1 5 8- 15 Li b e rty Av e nue J amai ca, NY 11433
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Employees engaged in the processing of a drug product lack the training required to perform their assigned functions.
Specifically, your firm lacks a specific training and verification schedule to evaluate the skills and expertise needed for personnel engaged in the visual inspection of finished drug products. Currently, according to SOP #4125, entitled "Visual Inspection -Finished Product," Version 1.1, effective date 3/22/18, an eye exam is to be completed <Redacted 4> for personnel responsible for the inspection of finished drug products. Yet, your firm does not have any written procedures that establish a requirement for personnel performing visual inspection to complete an eye exam, which tests for color-blindness and/or the ability to distinguish color. Moreover, eye exam testing for color-blindness and/or the ability to distinguish color are not collected or documented for personnel engaged in visual inspection.
Observation 2
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and foJlowed.
Specifically,
a) You have not adequately qualified the <Redacted B4> Building Monitoring System used to monitor pressure differentials between rooms within the aseptic processing suite, temperature of aseptic processing areas and room temperature drug storage areas, relative humidity of aseptic processing areas, temperature of refrigerated and frozen drug storage areas, temperature within incubators, and <Redacted B4> temperature. Currently, you have only performed installation qualification (IQ) and operational qualification (OQ) of the <Redacted B4> System. You have not completed the evaluation/summary report of the IQ/OQ, as well as the performance qualification (PQ) for the <Redacted B4> System prior to its use in monitoring aseptic operations and storage areas.
b) Your firm is not using <Redacted B4> during your <Redacted B4> sterilization of goggles, stir bars, stir bar retrievers, metal instruments, and vial trays. ...
Observation 3
Strict control is not exercised over labeling issued for use in drug product labeling operations.
Specifically,
a) Product and container labels are generated electronically using your firm's <Redacted B4> software and <Redacted B4> sofhvare, which are not validated systems.
c) Examination of packaging and labeling materials for suitability and correctness before packaging operations is not documented in the batch production records. Specifically, product syringe labels, which are printed by an operator "on-demand" in the ISO 7 Packaging Room, are examined by the same operator and then electronically sent to a pharmacist vial <Redacted B4> not a validated system) to be examined before the product syringe labels are released for labeling operations. However, the results of these printed product syringe label examinations are not recorded.
d) Records do not include the disposition of rejected labeling. The practice of the disposition of rejected labels due to the operator's and/or pharmacist's initial label review of printed product labels is not specified in any procedure. Printed labels that are determined to be defective are discarded; this is not documented anywhere.
Inspection dated Oct 23, 2015 by FDA (dates on the form not read): 5 observations
- Firm on the cover
- Pine Pharmaceuticals, 100 Colvin Woods Pkwy, CODE
- FEI number
- 3010943533
- Establishment type on the cover
- Outsourcing Facility Tonawanda, New York 14150
- FDA district office on the cover
- New York District 10/5, 6, 7, 9/2015 158-15 Liberty Avenue Jamaica, New York 11433-1034
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
There is a failure to thoroughly review the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
a). An investigation into out of specification test results for the potency of Vancomycin Injectable was no
t thorough . Lot 989@2 was released and partially distributed on 6/30/15 at 90.17% (specification of REDACTED (b) (4)%) as was lot 995@ 1 at 90.2% as was lot 996@2 at 90.65% with results obtained on 6/26/15. The entire batch for the three lots were stored in a freezer that lost power late on 6/26/15 and was out until 6/29/15. Samples for all three lots were retested for potency with respective results on 7/15/15 at 103.48, 86.01, and 104.1. Anot her lot, 1075@3 was found to be at 86.5% on 7/17/15 and was not released. The shelf life is 45 days frozen. One of the firm's conclusions was not to recall lots 989@2, 995@1, and 996@2 despite all three lots just at the lower limit of the potency and not being stored frozen for almost three days. ...
Observation 2
Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.
During processing of Bevacizumab 1.25mg/0.05mL lot 1740@2 on 10/05/15, we observed in the non-allergenic clean room the following: On the ISO 5 work area (in LAFW #I), there was clutter including a plastic bin containing various discarded articles as wrappers.
Observation 3
For each batch of drug product, there shall be appropriate laboratory determination of satisfactory conformance to final specifications for the drug product,including the identity and strength of each active ingredient, prior to release.
Released batches ofthe following products were tested for potency with testing methods that have not been validated: Vancomycin Intraocular Injection, Calcium Gluconate Topical gel, Ceftazidime Intraocular Injection, Mitomycin Ophthalmic Solution, and Moxifloxacin Intracameral Solution.
Observation 4
The labels and containers of your outsourcing facility's drug products do not include information required by section 503B(a)(10)(A) and (B).
Specifically,
The following information is not found on some of your drug product labels:
• The inactive ingredients, identified by established name and the quantity or proportion of each ingredient.
Furthermore, the following information is not found on the container labels for some drug products you produce: Information to facilitate adverse event reporting: www.fda.gov/medwatch and 1-800-FDA-1088. Examples of drug product labels that do not contain this information include:
• Calcium Gluconate Ophthalmic Irrigation 1% (5OOML) Solution • • • • • • •
Calcium Gluconate (PF) Inhalation 2.5% (5ML) Solution Calcium Gluconate Topical 2.5% (60GM) Gel Ceftazidime Preservative Free SDV for Intraocular Injection 22.5 MG/ ML Injectable Mitomycin Solution for Ophthalmic Use 0.02% (0.2 MG/ML) Moxifloxacin in BSS 150 MCG/0.1 ML Solution ...
Observation 5
Your outsourcing facility has not submitted a report to FDA identifying all products compounded during the previous six month period as required by section 503B(b)(2)(A). Examples of products that were compounded but not identified on the report submitted on June 29, 2015 include:
Calcium Gluconate (PF) 10% Injectable
•REDACTED (b) (4) Capsules • •Sodium Hydroxide 10% Solution
Calcium Gluconate Ophthalmic Irrigation Calcium Gluconate (PF) Inhalation 2.5%
State board of pharmacy records
State pharmacy license records for New York are not checked: the Office of the Professions’ online verification search requires an access key and a check that the user is a person, and its bulk verification files are released only on request. This index reads only that state’s board actions. Board actions source.
What this covers: Board of Regents disciplinary actions against pharmacy establishments from the Office of the Professions’ summaries for the pharmacy profession, which start in 1994 (105 of 105 list pages read). These are final Regents actions, mostly consent orders; open complaints and charges not yet decided are not listed. Actions against individual pharmacists are not copied. New York pharmacy licenses and registrations are not checked. Actions in the data are dated Jan 14, 1994 to May 19, 2026.
Nonresident licenses in other states
These boards list a nonresident license whose record names this pharmacy’s own name, city and state.
California State Board of Pharmacy, file dated Nov 6, 2026 (California).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| NSF 122 | Nonresident Outsourcing Facility | Pine Pharmaceuticals Llc | Tonawanda, NY | Active |
Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| AD-0010096 | Outsourcing Facility-Distributor | Pine Pharmaceuticals | TONAWANDA, NY | Active |
| A9-0001540 | Non Resident Pharmacy | Pine Pharmaceuticals | TONAWANDA, NY | Expired |
| AA-0000002 | Outsourcing Facility-Pharmacy | Pine Pharmaceuticals | TONAWANDA, NY | Expired |
| AA-X0000002 | Outsourcing Facility-Pharmacy | Pine Pharmaceuticals | TONAWANDA, NY | Closed |
Michigan Department of Licensing and Regulatory Affairs, file dated Nov 10, 2026 (Michigan).
| License | Type as the board gives it | Name on the board record | Location | Status |
|---|---|---|---|---|
| 5301011319 | Pharmacy | Pine Pharmaceuticals LLC | Tonawanda, NY | Active |
Close but not exact matches
These FDA records share a name or a former name with this pharmacy but did not meet this index’s matching rule (the same legal name with the same legal ending, in the same city and state), so they are kept on their own pages. Check them against the pharmacy you are looking for.
- Pine Pharmaceuticals, LLC, Tonawanda, NY: same city and state; names match only without the legal ending or through a dba name.
This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.
Sources
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Registered Outsourcing Facilities (503B)
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
- New York State Education Department disciplinary records
- California State Board of Pharmacy license file
- Delaware Division of Professional Regulation license file
- Michigan Department of Licensing and Regulatory Affairs license file
- California State Board of Pharmacy disciplinary records
- Delaware Division of Professional Regulation disciplinary records
Records last pulled Nov 15, 2026. Every entry links to the original public record.